are there any oral glp-1 drugs GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies MCT2D | The Benefits of

Connect with our health experts and get free assistance.

N Engl J Med 375(4):311322

population will be obese by 2030, which is defined as abnormal or excessive fat accumulation that presents a risk to health by the World Health Organization

Phase 2 data presented at ADA 2026 showed 22.5% placebo-adjusted weight loss at 48 weeks with no plateau, 54% obesity resolution versus 13% on placebo, and 87% of participants reaching at least 10% loss

Small-molecule composition of matter (COM) patents feature a classical generic Markush drawn around examples with the lead clinical candidate(s) at the core

Source [14] GLP-1 medication usage by age in the U.S